Search results
Showing 6346 to 6360 of 9009 results
Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in
Recommendation ID NG122/1 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell
'Trojan horse' treatment recommended for people with multiple myeloma
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
Home News Podcasts Backing the healthtech that changes lives Podcasts 31 March 2026 Listen About this episode When the right technology reaches
New take at home drug recommended for people with chronic lymphocytic leukaemia
Our latest draft guidance recommends pirtobrutinib, a new take at home tablet, that could give patients greater choice and reduce the need for frequent hospital visits.
NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments.
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
New life-extending treatment given the green light for people with rare form of bile duct cancer
A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.
Have your say on NICE's adoption of the new EQ-5D-5L value set
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.
First NICE recommended treatment for uncontrolled generalised myasthenia gravis
We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis (gMG) whose symptoms are not controlled by existing treatments.
Endometriosis now has its own fertility pathway in NICE guidance
The updated fertility guideline includes a brand-new section specifically for those with endometriosis who are struggling to conceive.
Injection for more than a million people to help prevent heart attacks and strokes recommended
People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.
MHRA-NICE pathway opens for business – everything you need to know to get started
Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.